P-PSMA-101 Generates Long-Lasting Response to Prostate Cancer, Mouse Study Shows

P-PSMA-101 Generates Long-Lasting Response to Prostate Cancer, Mouse Study Shows
Poseida Therapeutics’ P-PSMA-101 eliminated prostate cancer in all mice that were treated in a study and prevented it from returning in two-thirds, researchers reported. The long-lasting nature of the therapy surfaced in the finding that two out of three mice remained cancer-free at the end of the 42-day study, the team said. P-PSMA-101 is a CAR T-cell therapy that targets the PSMA protein found at high levels in prostate cancer. The name CAR T-cell comes from the approach used to fight cancer — modifying a person's own immune T-cells. Scientists said the treatment's long-lasting effect comes from the type of cells they modified: stem cell memory T-cells, or Tscms. Poseida presented the study's findings at the Society for Immunotherapy of Cancer 32nd Annual Meeting, in National Harbor, Maryland, Nov. 8-12. The title of the poster session was titled "PSMA‐specific CARTyrin T‐stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model.” P-PSMA has outperformed other CAR T-cell prostate cancer therapies in animal studies, Dr. Eric Ostertag, Poseida's CEO, said in a press release. “Future efforts will continue towards clinical application of P‐PSMA‐101 in patients with metastatic castrate resistance prostate cancer" — an advanced, hard-to-treat type. Studies suggest that P-PSMA-101 is better at keeping the cancer at bay than
Subscribe or to access all post and page content.